Predict your next investment

HEALTHCARE | Medical Equipment & Supplies
nexthealthinc.com

See what CB Insights has to offer

Stage

Seed | Alive

Total Raised

$100K

Last Raised

$100K | 9 yrs ago

About Next Health

Next Health is the manufacturer and marketer of a patient transfer and mobility system, the AgileLife Tranfer and Living System. The company develops and markets the ILS which is FDA approved, and has been successfully used in both institutional and home care settings. The core product is an integration of several assistive devices that automates the transfer of immobile individuals to and from a hospital bed and wheelchair without any need to lift the patient. This automated process eliminates significant care giver and patient cost while improving outcomes for all constituents in the long term care continuum.

Next Health Headquarter Location

112 Rowayton Avenue

Connecticut, 06853,

United States

203-939-1153

Latest Next Health News

The DNA Company Acquires AI Digital Therapeutics App for $30M to Form My Next Health

May 13, 2020

The DNA Company Acquires AI Digital Therapeutics App for $30M to Form My Next Health What You Should Know: – DNA Company acquires AI-based digital therapeutics app My Pain Sensei (MPS) to form My Next Health and is building a COVID-19 risk assessment platform to help people understand their risks of developing serious COVID-19 complications. – The acquisition combines functional genomics with conversational AI for patient self-management apps and disease tracking tools designed to inform clinician-patient interactions. Leading functional genomics provider  The DNA Company  todayannounced that it has acquired AI-based digital therapeutics app My Pain Sensei (MPS) for approximately $30M,forming  My NextHealth . The acquisition of MPS gives My Next Health an AI-based platform to develop multiple health applications. Self-Management through Digital Therapeutics As My Next Health, the company will focus on using precisionmedicine and digitaltherapeutics to develop genomics-based health management applications thatoffer patients genetic insights tailored to their unique biology. Theacquisition also provides My Next Health with a Class 1 Medical DeviceEstablishment License from Health Canada for applications related to chronicpain and COVID-19 . My Next Health’s MPS platform, which combines big data andgenomic insights with conversational AI and tracking tools, was developed byMPS through an engagement with IBM and includes access to more than 60 millionelectronic medical records and data from 32 billion claims. Creating COVID-19 Complications Risk Platform This data allows the platform to uncover key insights about identifiable symptoms, diagnoses, chronic pain treatment efficacy as well as for other chronic conditions. The My Next Health apps make those insights, tools, and interventions accessible to patients and their healthcare providers. As its first application, My Next Health is creating a COVID-19 application that assesses an individual’s risk profile for developing complications from the virus. The My Next Health COVID-19 application will work byanalyzing a person’s genetic pathways for inflammatory responses, insulinsensitivity and other genomic indicators through identifiable characteristicsthat factor into risk of COVID-19 complications. After determining an individual’srisk level, patients can use the application’s recommendations to help mitigatetheir risk using self-tracking tools that also can be shared with theirhealthcare providers. My Next Health will continue building in new functionalityover the next few months, with a fully functional application targeted forhealth systems or governments available this summer. Given the immediate public need created by the COVID-19pandemic, My Next Health is making a free online version of the applicationavailable to the public on May 15, which will include the conversational AI andintervention recommendations. The public version will be available at  www.mynexthealth.com . “The COVID-19 pandemic has revealed how a novel virus can upend the world’s healthcare system at a moment’s notice,” said Kashif Khan, CEO of My Next Health. “But, advances in functional genomics may allow us to better understand the underlying biological weaknesses that this novel virus exploits so that we can leverage existing treatment protocols to improve patient outcomes and reduce load on the healthcare system. The acquisition of MPS will help us tackle these and other problems.”

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Next Health Patents

Next Health has filed 3 patents.

The 3 most popular patent topics include:

  • Actuators
  • Appropriate technology
  • Chairs
patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/30/2018

6/18/2019

Paramotors, Chairs, Appropriate technology, Actuators, Furniture

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

1/30/2018

00/00/0000

00/00/0000

Grant Date

6/18/2019

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Related Topics

Paramotors, Chairs, Appropriate technology, Actuators, Furniture

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.